Milestone Pharmaceuticals, Inc.

Milestone Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of episodic cardiovascular conditions. Their primary focus is on etripamil, a novel, self-administered nasal spray calcium channel blocker, designed for the acute treatment of paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular rate (AFib-RVR). The company emphasizes a patient-centric approach, seeking to empower individuals with these heart rhythm disturbances to manage their episodes outside of a hospital setting.

Milestone has a strong leadership team with extensive experience in drug development, cardiovascular medicine, and commercialization. They are actively engaged in clinical trials and have published research supporting the potential benefits of etripamil. Their commitment to advancing scientific discovery and improving patient lives is evident through their partnerships with patient advocacy groups and their dedication to developing effective treatment solutions for episodic cardiovascular conditions.

Milestone Pharmaceuticals is a patient-centric, clinical-stage biopharmaceutical company dedicated to improving the lives of people living with cardiovascular conditions. They focus on developing self-administered treatments for acute episodes of paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular rate (AFib-RVR) outside of the emergency department or hospital setting. Their lead product, etripamil, is a nasal spray calcium channel blocker that aims to empower patients to terminate their SVT episodes or control their AFib whenever and wherever they occur.

Milestone Pharmaceuticals promotes a patient-centric culture, prioritizing the development of innovative therapies that improve the lives of people living with cardiovascular conditions. The company fosters a collaborative and supportive environment where employees are encouraged to contribute their expertise and work together to achieve shared goals. They emphasize a lean and cost-efficient model, focusing spending on developing treatment solutions that fill unmet needs.

Milestone Pharmaceuticals does not explicitly state its approach to diversity, equity, and inclusion on its website.